July 23, 2021
Engin Akyurt/Unsplash.com
Vaccine efficacy is still very high against the Delta variant in preventing hospitalizations and severe disease – arguably the outcomes we most care about.
With the highly infectious Delta coronavirus variant spreading at an alarming rate, the World Health Organization in late June urged people to again wear masks indoors – even those who are fully vaccinated. And on July 15, Los Angeles County, California, announced that it would again require masking up in public indoor spaces, regardless of vaccination status. This was followed by a recommendation – though not a mandate – from seven Bay Area counties for all to again don masks in public indoor settings.
Notably, the U.S. Centers for Disease Control and Prevention has not yet taken a similar stance. On July 12, National Nurses United, the nation's largest professional association for registered nurses, called on the CDC to reconsider in light of the spike in new infections and hospitalizations across the country. The Conversation asked Peter Chin-Hong, a physician who specializes in infectious diseases at the University of California, San Francisco, to help put into context the science behind these seemingly mixed messages.
There is clear and mounting evidence that – though rare – breakthrough COVID-19 infections can occur, even in the fully vaccinated. This is particularly true with emerging variants of concern.
The CDC has been following these data closely. By mid-July, nearly 60% of the U.S. population age 18 or older had been fully vaccinated. Infections in those who are fully vaccinated are rare, and serious outcomes from COVID-19 in that population are even rarer – though they do still occur. However, the CDC stopped tracking nonhospitalized cases of COVID-19 for people with and without symptoms among fully vaccinated individuals on May 1.
The risk of infection leading to serious illness and death, however, differs starkly between vaccinated and unvaccinated people.
Maybe. Preliminary data suggests that the rise of variants like Delta may increase the chance of breakthrough infections in people who received only their first vaccine dose. For instance, one not-yet peer-reviewed study found that a single dose of the Pfizer vaccine had an effectiveness of just 34% against the Delta variant, compared with 51% against the older Alpha variant in terms of warding off symptomatic disease.
But the data is more reassuring for those who have been fully vaccinated. After two doses, the Pfizer vaccine still provides strong protection against the Delta variant, according to real-world data from Scotland and a variety of other countries; and in preliminary studies out of Canada and England, researchers noted only a "modest" decrease in effectiveness against symptomatic disease from 93% for the Alpha variant to 88% for Delta.
One recent preliminary report from Israel is sobering, however. Before the Delta variant became widespread, from January to April, Israel reported that the Pfizer vaccine was 97% effective in preventing symptomatic disease. However, since June 6, with the Delta variant circulating more widely, the Pfizer vaccine has been 64% effective in preventing symptomatic disease, according to preliminary data reported by Israel's Ministry of Health in early July.
And in another new report that is not yet peer-reviewed, researchers compared blood serum antibodies from people vaccinated with Pfizer, Moderna and J&J vaccines and found that the J&J vaccine lent much lower protection against Delta, Beta and other variants, compared with the mRNA-based vaccines. As a result, the researchers suggest that J&J vaccine recipients would benefit from booster immunizations, ideally with one of the mRNA vaccines. However, this is a limited laboratory study that doesn't look at whether real people got sick, and contradicts a peer-reviewed study that found the J&J vaccine was protective against Delta eight months after vaccination.
In all reports and studies, however, vaccine efficacy is still very high against the Delta variant in preventing hospitalizations and severe disease – arguably the outcomes we most care about.
All of this emerging data supports the WHO recommendation that even fully vaccinated individuals continue to wear masks. Most of the world still has low vaccination rates, uses a range of vaccines with variable efficacy at preventing infection and has different burdens of circulating SARS-CoV-2 virus. In this context, it makes sense that the WHO would give a conservative recommendation to mask up for all.
The WHO's latest call for fully vaccinated people to continue wearing masks is primarily intended to protect the unvaccinated – which includes kids under age 12 who are not yet eligible for vaccines in the U.S. Unvaccinated people are at a substantially higher risk of getting infected with and transmitting SARS-CoV-2, and of developing complications from COVID-19.
And, again, there is still a low risk of infection for vaccinated people, but this risk differs regionally. In areas of highly circulating virus and poor vaccination rates, and with highly transmissible variants, there is a higher probability of infection in vaccinated individuals compared with people living in areas with lower levels of virus in the community.
I suspect the CDC is unlikely to pursue a universal U.S. recommendation to wear masks at this time. With an overall high countrywide vaccination rate and a low overall COVID-19 hospitalization and death burden, the U.S. has a COVID-19 landscape very different from most of the world.
Some experts also worry that sending an official message that the vaccinated should don masks may dissuade unvaccinated individuals from seeking vaccines.
There are emotional red flags and then there are more realistic red flags that may bring about a nationwide call for masking indoors for fully vaccinated people.
Having more than 100 cases of infection per 100,000 people per week is defined as "high" community transmission, the worst category, by the CDC. Los Angeles County, for example, has already surpassed that mark, with more than 10,000 coronavirus cases per week.
A more pragmatic measure for masking is the number of hospitalizations, because it is directly related to use of health care resources. Some researchers have proposed a threshold of five COVID-19 cases – averaged over several days – hospitalized per 100,000 people, which would potentially be a more ominous signal than infection rates. Los Angeles County has also surpassed that as well.
Surges will likely be a regional phenomenon based on how many people are fully vaccinated in an area. As long as hospitalizations and deaths remain generally manageable nationally, and with hospital capacity intact, the U.S. as a whole may not need to return to masking indoors for the fully immunized.
Peter Chin-Hong, Associate Dean for Regional Campuses, University of California, San Francisco
This article is republished from The Conversation under a Creative Commons license. Read the original article.
